Enck, Paul
Azpiroz, Fernando
Boeckxstaens, Guy
Elsenbruch, Sigrid
Feinle-Bisset, Christine
Holtmann, Gerald
Lackner, Jeffrey M.
Ronkainen, Jukka
Schemann, Michael
Stengel, Andreas
Tack, Jan
Zipfel, Stephan
Talley, Nicholas J.
Article History
First Online: 3 November 2017
Competing interests
: P.E. has received an unrestricted grant from SymbioPharm; has served as an adviser for Allergan, Almirall, AstraZeneca, Boehringer, Biocodex, Ferring, GA, Heel, SymbioPharm, TEVA and UCB; and has served as a speaker for Almirall, Bayer/Steigerwald, Boehringer, Chiesi, Heel and Sanofi. F.A. has received grant support from Danone, Clasado and Noventure; has served as an adviser for Danone, Clasado and Allergan; and has served as a speaker for Allergan. G.B. has served as an adviser for Reckitt-Benckiser and as speaker for Menarini. G.H. has received unrestricted grants from Bayer, Commonwealth Laboratories, the Falk Foundation and Takeda and has served as a speaker for Schwabe. M.S. has received unrestricted grants from Bayer/Steigerwald, Boehringer and Schwabe; has served as an adviser for Bionorica, Takeda and Almirall; and has served as a speaker for Almirall and Bayer/Steigerwald. J.T. has received research grants from Abide Therapeutics, Shire, Tsumura and Zeria; has given scientific advice to Abide Therapeutics, Alfa Wassermann, Allergan, Christian Hansen, Danone, Genfit, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Novartis, Nutricia, Ono Pharma, Rhythm, Shionogi, Shire, SK Life Sciences, Takeda, Theravance, Tsumura, Yuhan, Zealand and Zeria Pharmaceuticals; and has served as a speaker for Abbott, Allergan, AstraZeneca, Janssen, Kiowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda and Zeria. N.J.T. has received grant support from Abbott, Commonwealth Diagnostic Laboratories, GI Therapies, Janssen, Pfizer, Prometheus and Salix and has served as a consultant for Adelphi Values, Allergan, Ardelyx, CJ Healthcare, Commonwealth Diagnostic Laboratories, Danone, Forest Laboratories, Furiex, GI Care, GI Therapies, Napo Pharmaceuticals, Outpost Medicine, Samsung, Synergy, Takeda and Yuhan. All other authors declare no competing interests.